By

Luke Timmerman

6
Mar
2024

Early Detection, and Treatment, for Alzheimer’s: Valerie Daggett on The Long Run

Today’s guest on The Long Run is Valerie Daggett. Valerie is the founder and CEO of Seattle-based AltPep. This company is working on an unusual diagnostic-and-therapeutic strategy against Alzheimer’s disease. I wrote about the company in June 2023 when it raised $53 million in a Series B financing that included Section32, Alexandria Real Estate Equities, and Eli Lilly among others....
Read More
21
Feb
2024

Joy, Gratitude and Next Steps for Timmerman Traverse

Reporting this morning from Tanzania. I’m feeling joyful and grateful. My latest biotech team wrapped up another $1 million Timmerman Traverse fundraising campaign for the Damon Runyon Cancer Research Foundation. All 20 members of the team reached the summit of Kilimanjaro, the highest peak in Africa at 19,341 feet. We raised awareness of Damon Runyon’s national network of brilliant, brave...
Read More
9
Jan
2024

Investing in Healthy Aging: Jens Eckstein on The Long Run

Jens Eckstein is today’s guest on The Long Run. He’s an investment partner at Hevolution Foundation. It’s a Saudi Arabia-backed fund that supports basic research in healthy aging and invests in startups with partners to translate that science into interventions that help people live healthier, longer lives. These efforts are sometimes branded as increasing “healthspan” if not necessarily “lifespan.” Jens...
Read More
27
Dec
2023

Give to the Next Generation of Scientists

This is the time of year when many people sit down and think about the causes they want to support. I’m asking you to consider donating today to young scientists through the Damon Runyon Cancer Research Foundation. Why Young Scientists? Our system for funding science doesn’t do enough to support young people. The average age of a first-time NIH grant...
Read More
26
Dec
2023

Bispecific Antibodies for Cancer: Shelley Force Aldred and Nathan Trinklein on The Long Run

Today, I have a dynamic duo of scientific entrepreneurs on the show – Shelley Force Aldred and Nathan Trinklein. They are the co-founders of San Francisco-based Rondo Therapeutics. The company raised $67 million in a Series A financing announced in March 2022. Shelley is the CEO and Nathan is the chief scientific officer. Rondo is developing bispecific T-cell engaging antibodies...
Read More
1 2 3 45